All In Biotech

Drug Trial Radar · NCT01959841

Phase III Study of ASP2151 in Herpes Zoster Patients

Phase III Study of ASP2151 in Herpes Zoster Patients- A Double-blind, Valaciclovir-controlled Study

Last checked: Nov 19, 2026Latest source record: Nov 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 751 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

751

Actual

Start

Aug 2013

Primary completion

Jul 2015

Study completion Jul 10, 2015

Sponsor

Lead sponsor
Maruho Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in patients with herpes zoster.

Conditions

  • Herpes Zoster

Interventions

  • ASP2151Drug

    200 mg once daily or 400 mg once daily

  • valaciclovirDrug

    1000 mg three times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study TreatmentTime frame: 4days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Sapporo, Hokkaido, Japan

  • Site not named

    Yokohama, Kanagawa, Japan

  • Site not named

    Nakano-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.